Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2025

Login to access report north_east
Contact sales account_box

Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes. Treatment approaches vary by subtype, but rituximab in combination with chemotherapy remains the mainstay of treatment across NHL subtypes. Recent label expansions are giving hematologist-oncologists an ever-increasing array of treatment options, including Epkinly (Genmab / AbbVie) and Brukinsa (BeiGene) for relapsed/refractory (R/R) follicular lymphoma (FL) and Breyanzi (Bristol Myers Squibb) for R/R CLL, R/R FL, and R/R mantle-cell lymphoma (MCL). These advances, alongside shifting prescribing patterns and increasing competition, are reshaping the treatment of NHL and CLL.

Questions answered

  • What are the uptake and patient share of key therapies and regimens across all NHL / CLL subtypes, according to surveyed hematologist-oncologists?
  • How does physician prescribing of current treatments vary based on genetic mutations and CAR T-cell- and transplant-eligibility criteria?
  • How do drug-treatment rates vary across key B-cell NHL / CLL subtypes by line of therapy?
  • What are the key drivers and obstacles determining current prescribing patterns in NHL / CLL?
  • What are the clinical characteristics that physicians consider when prescribing CAR T-cell therapies and bispecific antibodies for the various NHL / CLL subtypes?

Primary research: Survey of 100 hematologist-oncologists in the United States fielded in December 2024

Key drugs covered: Breyanzi, Brukinsa, Calquence, Columvi, Epkinly, Imbruvica, Jaypirca, Kymriah, Lunsumio, rituximab, Tecartus, Venclexta, Yescarta

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

  • Understand the treatment landscape for a disease and how physicians make prescribing decisions.
  • Evaluate the drivers and obstacles that influence treatment selection.
  • Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
  • Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…
north_east
Report
Chronic Urticaria – Unmet Need – Unmet Need – Chronic Urticaria (US/EU)
Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…
north_east
Report
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current Treatment – Current Treatment: Physician Insights – Neuromyelitis Optica Spectrum Disorder (US)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic autoimmune neuroinflammatory disorder marked by optic neuritis and longitudinally extensive transverse myelitis, often leading to…
north_east
Report
Ovarian Cancer – Unmet Need – Unmet Need – Recurrent Platinum-Resistant Ovarian Cancer (US EU)
The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the…
north_east
Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east